Controlled trial of ornithine alpha ketoglutarate (OAKG) in patients with stroke. | Zendy

M. L. Woollard | Zendy; Rahel Pearson | Zendy; G Dorf | Zendy; Daniel Griffith | Zendy; I. M. James | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Controlled trial of ornithine alpha ketoglutarate (OAKG) in patients with stroke.

Author(s) -

M. L. Woollard,

Rahel Pearson,

G Dorf,

Daniel Griffith,

I. M. James

Publication year - 1978

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/01.str.9.3.218

Subject(s) - medicine , stroke (engine) , alpha (finance) , clinical trial , ornithine , randomized controlled trial , surgery , pediatrics , patient satisfaction , biochemistry , mechanical engineering , construct validity , chemistry , amino acid , arginine , engineering

A double blind controlled trial of ornithine alpha-ketoglutarate (OAKG) was carried out on 50 patients admitted to the Royal Free and Royal Northern Hospitals, London, suffering from a recent stroke. Significant improvement was found in patients treated with OAKG when examined on the fifth day of therapy as compared to their control cases. The therapy was given for 5 days. When the patients in the treated and the control groups were compared 10 days after the beginning of treatment, there were no differences between the 2 groups. Implications of these findings are discussed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research